



BioXL
Innovative BioPharma Solutions


CeaseCancer

A BioXL Initiative

**A Novel Anti-Cancer Therapy for
Pancreatic Cancer with Unique MoA
and High Safety Profile**

November 2024





ABOUT US

BioXL is dedicated to revolutionizing medical treatments and diagnostics by leveraging cutting-edge research and technology. We guide our projects from the initial discovery phase all the way to clinical development. Each initiative will be created as a new company to facilitate further development and commercialization. BioXL functions as a central hub, fostering innovation and collaboration.

OUR MISSION

Our mission at BioXL is to transform healthcare by developing innovative therapies that meet the needs of patients suffering from undertreated medical conditions, improving their quality of life.



OUR VISION AND VALUES

Our vision is to empower lives by providing innovative therapies that target undertreated medical needs and improve health outcomes globally.

EMPATHY

We understand and prioritize the experiences of patients and their families.

RESPONSIBILITY

We take accountability for our actions and their impact on society and the environment.

DIVERSITY

We embrace diverse perspectives to foster creativity and drive innovation.

CHALLENGE



“PANCREATIC CANCER IS A RELENTLESS SOURCE OF FRUSTRATION AND AN ENDURING CHALLENGE THAT CONTINUES TO TEST THE LIMITS OF OUR MEDICAL UNDERSTANDING AND THERAPEUTIC CAPABILITIES.” – PROF. IDO WOLF

PROBLEM

THE DISEASE

Pancreatic Ductal Adenocarcinoma (PDAC) accounts for **95%** of malignant pancreatic tumors.

PREVALENCE

The incidence of PDAC is **increasing in Western countries**.

THE NUMBERS

In **2024**, approximately **66,440 people** (34,530 men and 31,910 women) will be diagnosed with PDAC.

DEATHS

An estimated **51,750 people** (27,270 men and 24,480 women) will die from PDAC in 2024.

PROBLEM

POOR OUTCOMES

Despite advancements in medical technology, **less than 20%** of patients are cured.

SURVIVAL RATE

The **median survival** for patients with metastatic PDAC is about **11 months**.

TREATMENT

The **main treatment** for PDAC is chemotherapy.

Radiotherapy, targeted therapies and immunotherapies have been found to be largely ineffective.

NEW OPTIONS

There is an urgent need for more effective therapies to address these challenges.

SOLUTION

CEASECANCER

Universal anti-cancer drug,
alternative to chemotherapy



CEASECANCER

BioXL Ltd is launching CeaseCancer, a groundbreaking therapy.

TARGET


CeaseCancer targets Pancreatic Ductal Adenocarcinoma (PDAC), the most common and lethal form of pancreatic cancer.

METHOD

The therapy utilizes the natural tumor-suppressing properties of the Klotho protein.

SAFE AND EFFECTIVE

CeaseCancer offers a safer and more effective alternative to current treatments, as monotherapy or in combination with other treatment, such as chemotherapy.



PRODUCT OVERVIEW

CeaseCancer offers a range of innovative features and significant benefits that set it apart from traditional cancer therapies.

MECHANISM OF ACTION

CeaseCancer has a unique MoA not affected by chemotherapy, making it a versatile option for various cancers.

THERAPEUTIC USE

Can be used alone or with other treatments, such as chemotherapy for enhanced effectiveness, particularly in hard-to-treat cancers like PDAC and TNBC.

HIGH SAFETY PROFILE

As a recombinant version of a naturally occurring protein, CeaseCancer is recognized by the body, minimizing adverse effects.

ADMINISTRATION

Parenteral (intravenous or subcutaneous), allowing flexibility in treatment settings.

MARKET POTENTIAL



OVERVIEW

CeaseCancer is strategically positioned to tap into two lucrative markets, initially targeting Pancreatic Ductal Adenocarcinoma (PDAC) while also addressing Triple-Negative Breast Cancer (TNBC). Addressing other cancers will follow

\$4.01B

The pancreatic cancer drug market is forecasted to reach USD 4.01 billion by 2025, growing at a CAGR of 8.1%.

\$1.08B

Triple-negative breast cancer market is also significant, expected to grow to USD 1.08 billion by 2032.

CURRENT FUNDRAISING ROUND

PRE-SEED- \$1,000,000 USD

PRE-CLINICAL FOCUS

Funds will support testing rhKL-1 efficacy in PDx models and completing ADME and mini-tox studies.

FUNDRAISING AND PARTNERSHIPS

Achieving these milestones is expected to attract pharma partnerships, as indicated by prior feedback, and facilitate further fundraising.

REGULATORY AND VALUATION IMPACT

The data package will support a pre-IND meeting with the FDA, significantly boosting company valuation.

THE TECHNOLOGY

DEVELOPED BY PROF. IDO WOLF AND HIS TEAM

Prof. Wolf (MD, PhD) is currently the director of Oncology Division of Tel Aviv Medical center. Prof. Wolf's lab in Tel Aviv Medical Center (previously in Sheba Medical Center), led by Dr. Tamar Rubinek, is responsible for many different types of cancer research. The lab is the worldwide leader in cancer therapy aspects of Klotho.

LICENSED FROM SHEBA MEDICAL CENTER

Klotho technology is developed and IP-protected by Sheba Medical Center (Israel), Tel-Aviv Medical Center (Israel), and Cedar Sinai Medical Center (US). BioXL holds the worldwide exclusive license for Klotho technology from Sheba Medical Center (representing all three centers).

CEASECANCER TEAM



Project Leader

(To be announced)
Experienced in cancer
drug development



Prof. Ido Wolf, MD, PhD

Inventor, Clinical Advisor
Leading scientist, worldwide, in cancer
research. Inventor of “Klotho for cancer”.
Oncology Division Head in Tel-Aviv
Sourasky Medical center.
Endocrine-Oncology Laboratory Head



Tamar Rubinek, PhD

Scientific Advisor

WHO WE ARE



BioXL has brought together scientific experts and successful business leaders who share a passion for innovating. Our team has vast experience in biological sciences and in managing business platforms.

MEET THE BIOXL
TEAM



MEIR AZULAY
MSC

Founder, CEO



AVRAHAM LABAN
PHD

Founder, CTO



OURI FISCHEL
PHD, MBA

Founder, Business
Development



STEPHEN SIMES
BSC, MBA

Board Member,
Chairman, Mentor



TOONLEE NG
BSC, MBA

Board Member, Asia
Market Development



COMMITMENT

BioXL is committed to advancing medical treatments and diagnostics through innovative research and technology

DEVELOPMENT

BioXL develops its projects from discovery to clinical stage. Each project incorporates into a new company for further development and commercialization

OPERATIONS

BioXL operates as a HUB for biotechnology and biopharma startups

Bio-XL pipeline

	Discovery	Preclinical	IND enabling	Phase I	Area	Title
CancerPredict	▶				Cancer	Diagnostic test for improved cancer prognosis
CeaseCancer	▶				Cancer	Universal Anti-cancer drug as an alternative to chemotherapy
AMP Bio	▶				Anti-biotics	Anti-Microbial Peptides to treat multi-drug resistant pathogens
NES Pharma	▶				Neuro (CNS)	Delay age-related Cognitive symptoms with combination treatment
Marathon	▶				Longevity (age related diseases)	Carrier for Mitochondria in systemic administration to avoid immune response





PLEASE REACH OUT TO US
FOR THE FULL PRESENTATION,
WHICH INCLUDES DETAILED
INFORMATION ABOUT
CEASECANCER

MEIR AZULAY, CEO

Email: meir.biom@gmail.com

Tel: +972-54-953-6396

**Address: Ahavat Israel 9,
Sderot, Israel**

**WE LOOK
FORWARD TO
COLLABORATING
WITH YOU**